Aclarion Reports 31.5% Revenue Growth but Incurred Net Loss in Latest Quarter

Aclarion, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenues of $18,942, an increase of 31.5% compared to $14,407 in the same quarter of the previous year. For the nine months ended September 30, 2025, total revenues reached $57,251, marking a 61.3% increase from $35,492 in the prior year. Despite this revenue growth, Aclarion reported a net loss of $1,706,294 for the third quarter, compared to a loss of $1,366,176 in the same period last year. The nine-month net loss was $5,351,170, slightly higher than the $5,015,497 loss reported for the same period in 2024.

The company’s operational expenses also saw notable changes. Total operating expenses for the third quarter increased to $1,835,350, up from $1,289,033 in the prior year, driven primarily by a significant rise in sales and marketing costs, which surged by 171.7% to $632,409. Research and development expenses also increased by 54.3% to $302,037, reflecting the company's ongoing investment in its product development initiatives. General and administrative expenses rose modestly by 4.7% to $900,904.

Aclarion's balance sheet showed a substantial improvement in liquidity, with cash and cash equivalents rising to $11,341,336 as of September 30, 2025, compared to $453,661 at the end of 2024. This increase was bolstered by successful financing activities, including a public offering that raised approximately $14.6 million and a registered direct offering that brought in an additional $5.2 million. The company also reported a decrease in total liabilities, which stood at $699,747, down from $1,153,426 at the end of the previous fiscal year.

In terms of strategic developments, Aclarion has been expanding its market presence, particularly in the UK, where it has seen increased demand for its Nociscan reports following favorable local coverage decisions. The company is actively working to onboard more insurance payors to further enhance its revenue streams. As of November 10, 2025, Aclarion had 671,371 shares of common stock outstanding and continues to operate as an emerging growth company, allowing it to defer certain accounting standards.

Looking ahead, Aclarion's management expressed optimism about the continued growth of its revenue as it expands its customer base and increases scan volumes. However, the company acknowledged the need for additional funding to support ongoing technology development and commercialization efforts, indicating that it may seek further capital to sustain its growth trajectory.